Table 1.
Zebrafish animal models of myeloid malignancies.
| Gene name | Promoter and expression construct | Type | Refs |
|---|---|---|---|
| MYCN | MYCN-HSE-EGFP | AML | [58] |
|
| |||
| MYST3/NCOA2 | spi-1-MYST3/NCOA2-EGFP | AML | [70] |
|
| |||
| kRASG12D | B-actin-LoxP-EGFP-LoxP-kRASG12D; hsp70-Cre | MPD | [61] |
|
| |||
| NUP98-HOXA9 | spi-1-loxP-EGFP-loxP-NUP98-HOXA9; hsp70-Cre | MPN | [62] |
|
| |||
| Stat5.1 mutants | Constitutively active mutants of Stat5.1 | Tumor-like lesions; increased numbers of early and late myeloid cells, erythrocytes, and B cells | [65] |
|
| |||
| NPM1 mutant | pCS2cmv-NPM1c-EGFP | No AML; increased numbers of definitive hematopoietic cells | [66] |
|
| |||
| tel-jak2a | pCS2cmv-Flag-tel-jak2a; spi-1-Flag-tel-jak2a | No AML; anemic; perturbed intermediate cell mass; accumulation of large cells near the heart | [67] |
|
| |||
| AML1 | pCS2cmv-runx1 | No AML; enlarged heart and ectopic blood | [24] |
|
| |||
| AML1-ETO | pCS2cmv-RUNX1-CBF2T1 | No AML; defective development of blood and circulation and internal hemorrhaging | [24] |
|
| |||
| AML1-ETO | hsp-AML1-ETO | No AML; loss of gata1 hematopoietic cells in the posterior blood islands | [68] |
|
| |||
| AML1-ETO + Gro3 MO | hsp-AML1-ETO | No apparent AML; enhanced the accumulation of blast cells | [68] |
|
| |||
| FLT3-ITD | CMV-FLT3-ITD-T2a-EGFP | Ectopic myeloid cell expansion | |
| CMV-FLT3-TKD-T2a-EGFP | Ectopic myeloid cell expansion resistant to AC220 | [69] | |
| CMV-FLT3-ITD-TKD-T2a-EGFP | Conferred resistance to AC220 treatment | ||
AML: acute myeloid leukemia; MPD: myeloproliferative disorder; MPN: myeloproliferative neoplasm; MO: morpholino.